Skip to main content
Clinical Trials/NCT04342065
NCT04342065CompletedPhase 2

Efficacy of Pre-emptive Different Doses of Oral Pregabalin Versus Celecoxib on Sevoflurane and Analgesic Consumption in Patients Subjected for Elective Lumbar Spine Fixation Surgery: a Randomized Controlled Trial

South Egypt Cancer Institute1 site in 1 country200 target enrollmentStarted: January 1, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
pain control

Study Overview

Brief Summary

The anti-epileptic drugs such as gabapentin and other non-steroidal anti-inflammatory drugs (NSAID) such as celecoxib were used as a part of multimodal analgesia to control such pain. Gabapentin is an anticonvulsant drug that has analgesic effect in post-herpetic neuralgia, diabetic neuropathy, and neuropathic pain. Celecoxib is one of the NSAIDs, that its analgesic effect is reported in various studies by cyclooxygenase-2 (COX-2) inhibitor.

The aim of this randomized double-blinded study was to asses and compare the efficacy of using gabapentin versus celecoxib as a part of multimodal analgesia in perioperative hemodynamic control and pain relief in patients underwent posterior approach lumbar spine disc fixation surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
21 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •American society of anesthesiologists (ASA) I and II, aged between 21-60 years old scheduled to undergo elective posterior approach lumbar spine disc surgery

Exclusion Criteria

  • •Patients with a known sensitivity to celecoxib or pregabalin, psychotic disorder or cognitive impairment, history of drug dependency or substance addiction, history of chronic medical disease, the presence of coagulation disorders or pregnancy, were excluded from the study.

Arms & Interventions

Group (C)

Active Comparator

received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.

Intervention: Celecoxib capsules (Drug)

Group (G)

Active Comparator

received gabapentin 300 mg capsule 2 hours preoperative and the same dose 6 hours postoperative.

Intervention: Pregabalin 150mg (Drug)

Outcomes

Primary Outcomes

pain control

Time Frame: Change from Baseline Visual Analogue Scale every 4 hours for 48 hours (0=no pain 10=most sever pain)

Visual Analogue Scale for pain measurement.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
South Egypt Cancer Institute
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Alaa Ali M. Elzohry

Lecturer of Anesthesia, ICU and Pain Relief

Clinical Research Consultants, Inc.

Study Sites (1)

Loading locations...

Similar Trials